When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MTNB - Matinas And Amarin And Other News And Issues: The Good Bad And Ugly Of Biopharma
Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings, Inc.'s (NYSE:MTNB) stock grew over 200 percent in the past 12 months and is currently trading close to its 52-week high of $2.49. However, there are a few things which may hamper the stock’s upward trajectory. The company is in nuanced competition with Amarin (NASDAQ:AMRN), which recently won an FDA approval for the label extension for its Vascepa drug. The new approval expands the market for Vascepa to include patients with triglyceride levels above 150 mg/dL, whereas Matinas Bio is only targeting TGL > 500 MG/dL at present.